First patient enrolled in protect iv randomized controlled trial of impella

Danvers, mass.--(business wire)--abiomed (nasdaq:abmd) announced today that the first patient has been enrolled in protect iv, a large, prospective, multi-center randomized controlled trial (rct) that is designed to provide the level of clinical evidence needed to achieve a class i guideline recommendation for impella in high-risk percutaneous coronary intervention (hrpci). the first patient was enrolled at ascension st. john hospital in detroit by dr. ted schreiber, chief of cardiology at asce
ABMD Ratings Summary
ABMD Quant Ranking